IMPEDIMED LIMITED — Capital/Financing Update 2018

Mar 6, 2018

==> picture [226 x 43] intentionally omitted <==

7 March 2018

ASX ANNOUNCEMENT

ImpediMed and Sharp HealthCare Sign Agreement for SOZO[®]

Brisbane, Australia and Carlsbad, Calif. - ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status, is pleased to announce a multi-year commercial agreement with Sharp HealthCare to be a Centre of Excellence with SOZO[® ] with L-Dex[®] for their cancer care program.

Sharp HealthCare is a not-for-profit integrated regional health care delivery system located in San Diego, California. Sharp includes four acute-care hospitals, three specialty hospitals, two affiliated medical groups and a health plan. Sharp has approximately 2,600 physicians on medical staffs, more than 1,000 physicians in affiliated medical groups and more than 18,000 employees.

Under the agreement, multiple SOZO[®] systems will be utilised across several key Sharp HealthCare sites to establish best practices and calculate the economic impact of SOZO[®] . The agreement allows for expansion to all cancer patients within the Sharp HealthCare system. Installation and training have been completed for the first four sites.

“As one of the first integrated health systems to use SOZO[®] , Sharp is excited to bring this innovative technology for measuring tissue composition to cancer care across diverse care settings and to all types of cancer. The opportunity to demonstrate simultaneous improvements in patient experience, care management and a reduction in the cost of care is expected to go well beyond the early detection and management of lymphedema,” stated Nancy Harris, VP Oncology Service Line at Sharp HealthCare.

“We are very pleased to be expanding our relationship with Sharp HealthCare through a strategic partnership focused on best practices for SOZO[®] at this Centre of Excellence. The initial reception of SOZO[®] in the marketplace has been very encouraging, and the high level of interest is translating to strong early momentum for SOZO[®] ,” said Richard Carreon, Managing Director and CEO of ImpediMed.

Richard Carreon Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

Media Contact: Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.